newsfilter
← Latest News
GlobeNewswire·

NorthStrive Biosciences Announces Results from EL-32 Preclinical Combination Study with Semaglutide and Plans for Next Phase of Development

Study identifies preliminary lean-mass finding at the highest EL-32 dose while informing future preclinical development strategyResults advance NorthStrive Biosciences’ engineered probiotic platform targeting muscle